Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > LATEST
LATEST
-
REGULATORY MHLW Panel Endorses Lowe Syndrome as Designated Intractable Disease
February 28, 2024
-
BUSINESS Takeda to Outsource Dengue Vaccine Production to India’s Biological E
February 28, 2024
-
BUSINESS Mitsubishi Chemical Scraps Regenerative Medicine Unit
February 28, 2024
-
BUSINESS Radicava’s Brazil Launch Set for February 29: Mitsubishi Tanabe
February 28, 2024
-
BUSINESS Insmed Revs Up for Product Expansion in Japan, Arikayce Frontline Filing Set for 2026 with More to Follow
February 28, 2024
-
BUSINESS Japan Drug Market Tops 11 Trillion Yen for 1st Time Driven by Oncologics: IQVIA
February 27, 2024
-
REGULATORY NCC to Add Cabozantinib, Valemetostat to Pediatric, AYA Cancer Trial
February 27, 2024
-
ACADEMIA JSMO Panelists Urge Measures to Lure US Biotechs to Fight Drug Loss
February 27, 2024
-
REGULATORY Show Change in Development Trends before Seeking 2026 Reform: MHLW to Pharma
February 27, 2024
-
BUSINESS Shionogi Seeks Japan Nod for Akili’s Therapeutic App for Kids with ADHD
February 27, 2024
-
BUSINESS BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
-
BUSINESS Chugai Tapping Wearable to Objectively Gauge Pain, First Eyes Endometriosis Trial
February 26, 2024
-
ACADEMIA Pneumococcal Jabs Help Curb Pediatric Emergency Visits: Pediatrician
February 26, 2024
-
REGULATORY Japan Panel Backs Approval of Takeda’s Acquired Hemophilia A Drug
February 26, 2024
-
BUSINESS Novel Antibiotic Fetroja Approved in Taiwan: Shionogi
February 26, 2024
-
BUSINESS Maruho’s China Subsidiary Now Up and Running
February 26, 2024
-
BUSINESS Economic Terms for Obesity Drug Deal Disclosed by Lilly: Chugai
February 26, 2024
-
BUSINESS As Wegovy Hits Japan Market, Novo Re-Stresses Need for Proper Use
February 26, 2024
-
REGULATORY Drug Comparisons in Promotional Activities Allowed under 4 Conditions: MHLW
February 26, 2024
-
REGULATORY Deduction Formula for IP Box Tax Relief Now Clear as Preparations Move Ahead
February 22, 2024
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…